Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion

British Journal of Dermatology

Volumn 147, Issue 6, 2002, Pages 1227-1236

  Sterry, Wolfram ^a   Ruzicka, T ^b   Herrera, E ^c   Takwale, A ^d   Bichel, J ^e   Andres, K ^f   Ding, L ^f   Thissen, M R T M ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b University Clinic of Dermatology   (Germany)

^c Hospital Clínico de Malaga   (Spain)

^d WALSGRAVE HOSPITAL   (United Kingdom)

^e 3M Deutschland GmbH   (Germany)

^f 3M COMPANY   (United States)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Basal cell carcinoma; Imiquimod; Nodular; Superficial

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DEVICE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EROSION; ERYTHEMA; EUROPE; FEMALE; FEVER; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NECK PAIN; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN BLEEDING; SKIN BURNING SENSATION; SKIN DISEASE; SKIN EDEMA; SKIN INDURATION; SKIN INFLAMMATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN ULCER; SUPERFICIAL CANCER; TECHNIQUE; TUMOR BIOPSY; TUMOR VOLUME; DRUG ADMINISTRATION; DRUG ERUPTION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROTECTIVE CLOTHING; SKIN TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCLUSIVE DRESSINGS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036886426     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.05069.x     Document Type: Article

References (9)

1. Harrison C, Jenski L, Voychehovski R, Bernstein D. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988; 10: 209-24.
2. Sidky Y, Borden E, Weeks C et al. Inhibition of murine tumour growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992; 52: 3528-33.
3. Testerman T, Imbertson L, Reiter M et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leuk Biol 1995; 58: 365-72.
4. Beutner K, Geisse J, Helman D et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
5. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
6. Shumack S, Robinson J, Kossard S et al. Efficacy of topical imiquimod 5% cream for the treatment of nodular basal cell carcinoma: comparison of dosage regimens. Arch Dermatol, in press.
7. Zhai H, Maibach H. Effects of skin occlusion on percutaneous absorption: an overview. Skin Pharmacol Appl Skin Physiol 2001; 14: 1-10.
8. Rook et al. Textbook of Dermatology, 6th edn. Oxford: Blackwell Science Ltd, 1998.
9. Geisse J, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol, in press.